Insights · From the desk
Thinking on cross-border life-science deals.
Field notes, deal mechanics, and corridor intelligence from the partners who run the mandates. Written for principals weighing a transaction – not for the feed.
Selected reading
Discuss a mandate ->
Signals worth a second look.
Long-form analysis on the deals shaping the Africa-Gulf-Europe-USA corridor, and the structures behind them.
Why the Gulf is becoming the pivot point for out-licensing into emerging markets.
Continue reading ->
Mar 03
11 min
Pricing an asset before the term sheet: where founders leave value on the table.
Deal Intelligence
Feb 19
8 min
Reading a buyer’s diligence questions for what they really signal.
Licensing
Feb 06
12 min
GLP-1 fast-followers and the licensing window that is closing faster than people think.
Therapeutic Trends
Jan 24
10 min
The case for a NewCo when the asset is right but the balance sheet is wrong.
NewCo & Capital
Jan 12
14 min
Cell & gene programs are crossing borders – the manufacturing math finally works.
Therapeutic Trends
Dec 18
7 min
What an NDA-first process actually protects, and what it cannot.
Deal Intelligence
Newsletters
Pharma deal intelligence, delivered.
PharmaSync Brief · Monthly
The cross-border deal feed.
Corridor signals, modality shifts, and the structures behind the month’s most relevant transactions – read by principals across four markets.
Deal Radar · Weekly
Every cross-border deal that mattered, in five minutes.
A tight weekly digest of licensing, M&A, and partnership activity across Africa, the Gulf, Europe, and the United States.
Engagement
Begin a confidential conversation.
Contact us ->
Response within 24 hours